

Gerrit Jan Wolbink

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8102588/gerrit-jan-wolbink-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137
papers

11,504
citations

57
h-index

106
g-index

140
ext. papers

13,062
ext. citations

5.5
avg, IF

5.87
L-index

#	Paper	IF	Citations
137	Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. <i>Nature Genetics</i> , 2010 , 42, 508-14	36.3	969
136	C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?. <i>Circulation</i> , 1999 , 100, 96-102	16.7	665
135	Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 1460-8	27.4	538
134	Common variants at CD40 and other loci confer risk of rheumatoid arthritis. <i>Nature Genetics</i> , 2008 , 40, 1216-23	36.3	416
133	Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. <i>Arthritis and Rheumatism</i> , 2005 , 52, 2740-50		399
132	Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 921-6	2.4	396
131	Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006 , 54, 711-5		384
130	Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2013 , 9, 164-72	8.1	292
129	Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. <i>Nature Genetics</i> , 2009 , 41, 1313-8	36.3	272
128	C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. <i>Circulation</i> , 1997 , 95, 97-103	16.7	250
127	Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 104-9	2.4	205
126	Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 490-4	2.4	189
125	Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 1122-6	6.1	169
124	Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64, 704-7	2.4	165
123	Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1914-5	2.4	161
122	Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3226-33		158
121	Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 817-21	2.4	155

120	Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. <i>Current Opinion in Immunology</i> , 2008 , 20, 431-5	7.8	151
119	Dealing with immunogenicity of biologicals: assessment and clinical relevance. <i>Current Opinion in Rheumatology</i> , 2009 , 21, 211-5	5.3	138
118	A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. <i>Journal of Immunological Methods</i> , 2010 , 362, 82-8	2.5	135
117	Differential effect of drug interference in immunogenicity assays. <i>Journal of Immunological Methods</i> , 2011 , 372, 196-203	2.5	132
116	Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 253-6	2.4	132
115	The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 284-8	2.4	131
114	The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 128-33 ^{2,4}	2.4	131
113	Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. <i>PLoS Genetics</i> , 2013 , 9, e1003394	6	127
112	Key findings towards optimising adalimumab treatment: the concentration-effect curve. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 513-8	2.4	122
111	Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 578-85	2.4	119
110	Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B. <i>Human Mutation</i> , 2009 , 30, E640-50	4.7	119
109	Effects on leukocytes after injection of tumor necrosis factor into healthy humans. <i>Blood</i> , 1992 , 79, 693-698	4.7	114
108	Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. <i>Archives of Dermatology</i> , 2010 , 146, 127-32		113
107	Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 88-91	2.4	106
106	Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 531-5	2.4	105
105	Application of a monoclonal antibody against a neopeptide on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. <i>Journal of Immunological Methods</i> , 1993 , 163, 67-76	2.5	101
104	The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 1139-44	2.4	100
103	Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1252-4	2.4	98

102	Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. <i>Science</i> , 2021 , 371,	33.3	98
101	Inhibition of human complement by beta-glycyrrhetic acid. <i>Immunology</i> , 1997 , 90, 115-20	7.8	86
100	Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 593-600	5	84
99	Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1324-30		84
98	Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. <i>Arthritis and Rheumatism</i> , 2011 , 63, 877-83		83
97	The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 311-4	2.4	82
96	Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1484-90		78
95	The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. <i>Arthritis Research and Therapy</i> , 2010 , 12, 217	5.7	76
94	Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1849-61		74
93	Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 958-61	2.4	73
92	Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005 , 32, 252-5	4.1	73
91	Long-term measurement of anti-adalimumab using pH-shift-anti-idiotypic antigen binding test shows predictive value and transient antibody formation. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1680-6	2.4	72
90	Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNF biologics in rheumatic diseases. <i>Clinical Rheumatology</i> , 2013 , 32, 1429-35	3.9	70
89	Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 624-5	2.4	70
88	Complement activation in patients with sepsis is in part mediated by C-reactive protein. <i>Journal of Infectious Diseases</i> , 1998 , 177, 81-7	7	69
87	A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1303-9	2.4	68
86	Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1787-8	2.4	67
85	Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 409-12	2.4	65

84	Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. <i>Journal of Immunological Methods</i> , 2012 , 375, 93-9	2.5	63
83	Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 361-8	2.4	61
82	Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3850-5		61
81	Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. <i>Journal of Immunological Methods</i> , 2015 , 418, 29-38	2.5	57
80	Immunogenicity of biological therapeutics: from assay to patient. <i>Current Opinion in Rheumatology</i> , 2012 , 24, 306-11	5.3	56
79	Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 396-401	2.4	55
78	Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 2178-82	2.4	55
77	Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1170-6	2.4	54
76	High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	54
75	Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study. <i>Rheumatology</i> , 2013 , 52, 547-53	3.9	52
74	Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study. <i>Arthritis Research and Therapy</i> , 2010 , 12, R221	5.7	52
73	Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges. <i>Oncologist</i> , 2016 , 21, 1260-5	12.68	52
72	IgG4 production against adalimumab during long term treatment of RA patients. <i>Journal of Clinical Immunology</i> , 2012 , 32, 1000-6	5.7	51
71	A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, e15	2.4	49
70	Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody. <i>Analytical Biochemistry</i> , 2011 , 411, 271-6	3.1	48
69	Toll-like receptor triggering augments activation of human mast cells by anti-citrullinated protein antibodies. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1915-23	2.4	45
68	Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 484-487	2.4	44
67	Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies. <i>Journal of Biological Chemistry</i> , 2014 , 289, 34482-8	5.4	44

66	Detection of soluble human granzyme K in vitro and in vivo. <i>European Journal of Immunology</i> , 2005 , 35, 2940-8	6.1	43
65	Interplay of complement and cytokines in the pathogenesis of septic shock. <i>Immunopharmacology</i> , 1992 , 24, 135-48		43
64	Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008 , 35, 1972-7	4.1	43
63	Tumour necrosis factor {alpha} blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1281-5	2.4	42
62	Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 133-4	2.4	42
61	The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2. <i>British Journal of Cancer</i> , 1992 , 65, 96-101	8.7	42
60	Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1825-9	2.4	41
59	Complement activation induced by ischemia-reperfusion in humans: a study in patients undergoing partial hepatectomy. <i>Journal of Hepatology</i> , 2000 , 32, 783-91	13.4	41
58	Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. <i>Lancet Rheumatology</i> , 2021 , 3, e778-e788	14.2	40
57	Immunogenicity of TNF-Inhibitors. <i>Frontiers in Immunology</i> , 2020 , 11, 312	8.4	39
56	Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab. <i>Arthritis and Rheumatism</i> , 2003 , 48, 2996-7		37
55	Monoclonal anti-citrullinated protein antibodies selected on citrullinated fibrinogen have distinct targets with different cross-reactivity patterns. <i>Rheumatology</i> , 2013 , 52, 631-5	3.9	36
54	Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 1697-701	2.4	35
53	Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2791-802		32
52	Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 837-848	5.1	30
51	Capillary blood microsampling to determine serum biopharmaceutical concentration: Mitra micro-sampler vs dried blood spot. <i>Bioanalysis</i> , 2018 , 10, 815-823	2.1	30
50	Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 2217-9	2.4	30
49	Antibodies to IgG4 hinge can be found in rheumatoid arthritis patients during all stages of disease and may exacerbate chronic antibody-mediated inflammation. <i>Arthritis and Rheumatology</i> , 2014 , 66, 1133-40	9.5	30

48	Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab. <i>Arthritis Research and Therapy</i> , 2015 , 17, 78	5.7	28
47	Therapeutic TNF Inhibitors can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange. <i>Scientific Reports</i> , 2016 , 6, 32747	4.9	28
46	The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting. <i>British Journal of Dermatology</i> , 2015 , 173, 855-7	4	27
45	Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusion cycle: an open-label pharmacokinetic cohort study. <i>BMC Musculoskeletal Disorders</i> , 2011 , 12, 12	2.8	27
44	High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 1249-50	2.4	25
43	Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity. <i>Journal of Rheumatology</i> , 2015 , 42, 1638-46	4.1	23
42	Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study. <i>BMC Musculoskeletal Disorders</i> , 2012 , 13, 184	2.8	23
41	Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population. <i>Lancet Rheumatology, The</i> , 2020 , 2, e583-e585	14.2	23
40	Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	22
39	Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti-adalimumab in patients with inflammatory diseases. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 2474-2484	3.8	22
38	IgG Subclass Specificity Discriminates Restricted IgM Rheumatoid Factor Responses From More Mature Anti-Citrullinated Protein Antibody-Associated or Isotype-Switched IgA Responses. <i>Arthritis and Rheumatology</i> , 2015 , 67, 3124-34	9.5	22
37	The effects of continuous venovenous hemofiltration on coagulation activation. <i>Critical Care</i> , 2006 , 10, R150	10.8	21
36	Adverse events after first COVID-19 vaccination in patients with autoimmune diseases. <i>Lancet Rheumatology, The</i> , 2021 , 3, e542-e545	14.2	20
35	The minipig as an alternative non-rodent model for immunogenicity testing using the TNF α blockers adalimumab and infliximab. <i>Journal of Immunotoxicology</i> , 2014 , 11, 62-71	3.1	17
34	Anti-Hinge Antibodies Recognize IgG Subclass- and Protease-Restricted Neoepitopes. <i>Journal of Immunology</i> , 2017 , 198, 82-93	5.3	16
33	Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site. <i>Journal of Allergy and Clinical Immunology</i> , 2017 , 139, 1035-1037.e6	11.5	16
32	IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008 , 35, 425-8	4.1	16
31	Type I interferon response gene expression in established rheumatoid arthritis is not associated with clinical parameters. <i>Arthritis Research and Therapy</i> , 2016 , 18, 290	5.7	15

30	Using monoclonal antibodies as an international standard for the measurement of anti-adalimumab antibodies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016 , 120, 198-201	3.5	15
29	Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1285-1288	2.4	13
28	Restricted immune activation and internalisation of anti-idiotypic complexes between drug and antidrug antibodies. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1471-1479	2.4	13
27	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for and CD39. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1055-1061	2.4	12
26	The acute-phase response is not predictive for the development of arthritis in seropositive arthralgia - a prospective cohort study. <i>Journal of Rheumatology</i> , 2012 , 39, 1914-7	4.1	12
25	Nanomolar to sub-picomolar affinity measurements of antibody-antigen interactions and protein multimerizations: fluorescence-assisted high-performance liquid chromatography. <i>Analytical Biochemistry</i> , 2013 , 437, 118-22	3.1	10
24	Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, e24	2.4	9
23	The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 306-313	2.2	9
22	Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2019 , 48, 266-270	1.9	7
21	Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2019 , 21, 66	5.7	7
20	Divergent chemokine receptor expression and the consequence for human IgG4 B ₁ cell responses. <i>European Journal of Immunology</i> , 2020 , 50, 1113-1125	6.1	7
19	Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice. <i>International Journal of Rheumatic Diseases</i> , 2019 , 22, 869-873	2.3	5
18	Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study. <i>Journal of Investigative Dermatology</i> , 2020 , 140, 2129-2137	4.3	4
17	Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	4
16	Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 655-62	2.2	4
15	Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic/pharmacodynamic simulations. <i>European Journal of Clinical Pharmacology</i> , 2020 , 76, 1417-1425	2.8	3
14	Progression of structural damage is not related to rituximab serum levels in rheumatoid arthritis patients. <i>Rheumatology</i> , 2013 , 52, 1462-6	3.9	3
13	The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients. <i>Rheumatology</i> , 2020 , 59, 1703-1708	3.9	3

12	Comment on Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trialSby Tanaka. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e172	2.4	3
11	Identification of Clinically and Pathophysiologically Relevant Rheumatoid Factor Epitopes by Engineered IgG Targets. <i>Arthritis and Rheumatology</i> , 2020 , 72, 2005-2016	9.5	2
10	Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial.. <i>Scandinavian Journal of Rheumatology</i> , 2022 , 1-8	1.9	2
9	Elevated Fab glycosylation of anti-hinge antibodies. <i>Scandinavian Journal of Rheumatology</i> , 2021 , 1-8	1.9	1
8	Effects on leukocytes after injection of tumor necrosis factor into healthy humans. <i>Blood</i> , 1992 , 79, 693-698	6.8	1
7	Comprehensive evaluation of microneedle-based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 3162-3176	3.8	1
6	Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider. <i>RMD Open</i> , 2022 , 8, e002216	5.9	1
5	Differences in Palmoplantar Pustulosis and Psoriasis Vulgaris in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Treated with Biological Therapy. <i>Journal of Rheumatology</i> , 2019 , 46, 117-118	4.1	0
4	Do C-reactive protein levels help predict onset of rheumatoid arthritis in women?. <i>Nature Clinical Practice Rheumatology</i> , 2007 , 3, 318-9		
3	Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial. <i>Trials</i> , 2021 , 22, 406	2.8	
2	Response to: Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS studySby Marotte. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e82	2.4	
1	Response to: Comment on lSAmi titled Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trialSby den Broeder. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, e68	2.4	